Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Overexpression of Neuron-Specific Enolase as a Prognostic Factor in Patients with Gastric Cancer

  • Park, Taejin (Department of Surgery, Gyeongsang National University School of Medicine) ;
  • Lee, Young-Joon (Department of Surgery, Gyeongsang National University School of Medicine) ;
  • Jeong, Sang-Ho (Department of Surgery, Gyeongsang National University School of Medicine) ;
  • Choi, Sang-Kyung (Department of Surgery, Gyeongsang National University School of Medicine) ;
  • Jung, Eun-Jung (Department of Surgery, Gyeongsang National University School of Medicine) ;
  • Ju, Young-tae (Department of Surgery, Gyeongsang National University School of Medicine) ;
  • Jeong, Chi-Young (Department of Surgery, Gyeongsang National University School of Medicine) ;
  • Park, Miyeong (Department of Anesthesiology, Gyeongsang National University School of Medicine) ;
  • Hah, Young-Sool (Gyeongnam Regional Cancer Center, Gyeongsang National University School of Medicine) ;
  • Yoo, Jiyun (Department of Microbiology/Research Institute of Life Science, Gyeongsang National University College of Natural Sciences) ;
  • Ha, Woo-Song (Department of Surgery, Gyeongsang National University School of Medicine) ;
  • Hong, Soon-Chan (Department of Surgery, Gyeongsang National University School of Medicine) ;
  • Ko, Gyung Hyuck (Gyeongnam Regional Cancer Center, Gyeongsang National University School of Medicine)
  • Received : 2017.05.08
  • Accepted : 2017.07.28
  • Published : 2017.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Enolase is a cytoplasmic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in the glycolytic pathway. The aim of this study was to investigate whether the overexpression of neuron-specific enolase (NSE) can serve as a prognostic factor in patients with gastric cancer (GC). Materials and Methods: To assess its prognostic value in GC, NSE expression was measured by immunohistochemistry in a clinically annotated tissue microarray comprising of 327 human GC specimens. Cytoplasmic NSE expression was scored from 0 to 4, reflecting the percentage of NSE-positive cells. Results: In terms of histology as per the World Health Organization criteria (P=0.34), there were no differences between the NSE overexpression (NSE-OE) and NSE underexpression (NSE-UE) groups. The NSE-OE group showed a significantly lower rate of advanced GC (P<0.01), lymph node metastasis (P=0.01), advanced stage group (P<0.01), cancer-related death (P<0.01), and cancer recurrence (P<0.01). Additionally, a Kaplan-Meier survival analysis revealed that the NSE-OE group had longer cumulative survival times than the NSE-UE group (log-rank test, P<0.01). However, there were no significant differences in the serum levels of NSE expression in patients with GC and healthy volunteers (P=0.28). Conclusions: Patients with NSE overexpressing GC tissues showed better prognostic results, implying that NSE could be a candidate biomarker of GC.

Keywords

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
  2. Lee HJ, Yang HK, Ahn YO. Gastric cancer in Korea. Gastric Cancer 2002;5:177-182. https://doi.org/10.1007/s101200200031
  3. Pinson P, Joos G, Watripont P, Brusselle G, Pauwels R. Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer. Respiration 1997;64:102-107. https://doi.org/10.1159/000196651
  4. Cooper EH. Neuron-specific enolase. Int J Biol Markers 1994;9:205-210. https://doi.org/10.1177/172460089400900401
  5. Kaiser E, Kuzmits R, Pregant P, Burghuber O, Worofka W. Clinical biochemistry of neuron specific enolase. Clin Chim Acta 1989;183:13-31. https://doi.org/10.1016/0009-8981(89)90268-4
  6. Jorgensen LG, Osterlind K, Hansen HH, Cooper EH. Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC). Br J Cancer 1994;70:759-761. https://doi.org/10.1038/bjc.1994.391
  7. Kimura M, Tsuda H, Morita D, Ichikura T, Ogata S, Aida S, et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 2004;445:255-262. https://doi.org/10.1007/s00428-004-1048-7
  8. Chen CD, Wang CS, Huang YH, Chien KY, Liang Y, Chen WJ, et al. Overexpression of CLIC1 in human gastric carcinoma and its clinicopathological significance. Proteomics 2007;7:155-167. https://doi.org/10.1002/pmic.200600663
  9. Cho HJ, Baek KE, Park SM, Kim IK, Choi YL, Cho HJ, et al. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer. Clin Cancer Res 2009;15:2612-2619. https://doi.org/10.1158/1078-0432.CCR-08-2192
  10. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008;52:738-746. https://doi.org/10.1111/j.1365-2559.2008.03021.x
  11. Cho JY. Molecular diagnosis for personalized target therapy in gastric cancer. J Gastric Cancer 2013;13:129-135. https://doi.org/10.5230/jgc.2013.13.3.129
  12. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
  13. Corso G, Pedrazzani C, Marrelli D, Pascale V, Pinto E, Roviello F. Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma. Arch Surg 2009;144:722-727. https://doi.org/10.1001/archsurg.2009.42
  14. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008;15:1968-1976. https://doi.org/10.1245/s10434-008-9927-9
  15. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, et al. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010;295:144-153. https://doi.org/10.1016/j.canlet.2010.04.025
  16. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, et al. p21 expression is a prognostic factor in patients with p53-negative gastric cancer. Cancer Lett 2000;148:181-188. https://doi.org/10.1016/S0304-3835(99)00335-3
  17. Yu D, Du K, Liu T, Chen G. Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC Patients. Int J Mol Sci 2013;14:11145-11156. https://doi.org/10.3390/ijms140611145
  18. Dong Y, Zheng X, Yang Z, Sun M, Zhang G, An X, et al. Serum carcinoembryonic antigen, neuron-specific enolase as biomarkers for diagnosis of nonsmall cell lung cancer. J Cancer Res Ther 2016;12:34-36. https://doi.org/10.4103/0973-1482.191626
  19. Sosonkina N, Hong SK, Starenki D, Park JI. Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. Genes Genomics 2014;36:829-841. https://doi.org/10.1007/s13258-014-0217-6
  20. Lee HS, Kim WH. Tissue array methods for high-throughput clinicopathologic research. Cancer Res Treat 2006;38:1-6. https://doi.org/10.4143/crt.2006.38.1.1

Cited by

  1. LPS promotes the expression of PD‐L1 in gastric cancer cells through NF‐κB activation vol.119, pp.12, 2017, https://doi.org/10.1002/jcb.27329
  2. Clinical significance of serum neuron-specific enolase in gastric adenocarcinoma vol.99, pp.16, 2017, https://doi.org/10.1097/md.0000000000019829
  3. MicroRNA profiles in five pairs of early gastric cancer tissues and adjacent non‑cancerous tissues vol.22, pp.2, 2017, https://doi.org/10.3892/ol.2021.12856